10-Q: Voyager Therapeutics Reports Q3 Loss, Novartis Cuts Programs

Voyager Therapeutics reported a significant increase in net loss and a sharp decline in collaboration revenue for Q3 2025, alongside a partial termination of key programs by Novartis.

Summary

• Voyager Therapeutics reported a net loss of $92.3 million for the nine months ended September 30, 2025, a substantial increase from $30.5 million for the same period in 2024.
• Collaboration revenue decreased significantly to $25.0 million for the nine months ended September 30, 2025, compared to $73.7 million for the same period in 2024.
• Net cash used in operating activities surged to $102.2 million for the nine months ended September 30, 2025, from $0.8 million in the prior year period.
• Novartis partially terminated its 2022 Option and License Agreement for two programs (one Initial Target and the Direct License Target), effective February 1, 2026, eliminating future milestone and royalty eligibility for these programs.
• Neurocrine Biosciences discontinued two 2019 Discovery Programs on April 30, 2025, with rights reverting to Voyager, also eliminating future milestones and royalties for these programs.
• The company initiated a Phase 1 multiple ascending dose (MAD) clinical trial for VY7523 (anti-tau antibody for Alzheimer's disease) in February 2025, with initial data expected in the second half of 2026.
• An Investigational New Drug (IND) application and clinical trial initiation for VY1706 (tau silencing gene therapy for Alzheimer's disease) are anticipated in 2026.
• Preclinical studies for the ALPL-VYGR-NeuroShuttle, a non-viral delivery platform, demonstrated sustained brain expression over three weeks in murine models.
• The SOD1-ALS gene therapy and anti-A antibody gene therapy programs were deprioritized in Q3 2025.
• As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $229.0 million, expected to fund operations into 2028.

Sentiment

Score: 3

Explanation: The significant increase in net loss and cash burn, coupled with a sharp decline in collaboration revenue, indicates deteriorating financial performance. The partial termination of two Novartis programs and the discontinuation of two Neurocrine programs are material setbacks, reducing future revenue potential. While the cash runway into 2028 provides some stability, the overall operational and financial outlook is challenging, warranting a low sentiment score.

Positives

• Cash, cash equivalents, and marketable securities of $229.0 million as of September 30, 2025, are expected to be sufficient to meet operating expenses and capital expenditure requirements into 2028.
• Initiation of a Phase 1 MAD clinical trial for VY7523 in early Alzheimer's disease patients in February 2025, with initial data anticipated in H2 2026.
• Preclinical studies for the ALPL-VYGR-NeuroShuttle non-viral delivery platform showed sustained brain expression over three weeks, demonstrating potential for enhanced CNS delivery.
• Neurocrine initiated a preclinical toxicology study for a fourth development candidate in a gene therapy program, triggering a $3.0 million milestone payment expected in Q4 2025.
• Advancement of proprietary pipeline programs for Alzheimer's disease, including VY7523 and VY1706, and the non-viral NeuroShuttle platform.

Negatives

• Net loss significantly increased to $92.3 million for the nine months ended September 30, 2025, from $30.5 million in the prior year period.
• Collaboration revenue decreased by $48.7 million to $25.0 million for the nine months ended September 30, 2025, primarily due to a $15.0 million amendment fee recognized in 2024 and reduced revenue from the 2023 Neurocrine Collaboration Agreement.
• Net cash used in operating activities increased substantially to $102.2 million for the nine months ended September 30, 2025, compared to $0.8 million in the prior year.
• Novartis partially terminated its 2022 Option and License Agreement for two programs, effective February 1, 2026, resulting in the loss of future milestone payments and royalties for those programs.
• Neurocrine discontinued two 2019 Discovery Programs in April 2025, leading to the loss of potential milestone and royalty payments for those programs.
• Deprioritization of the SOD1-ALS gene therapy and anti-A antibody gene therapy programs in Q3 2025.

Risks

• The company has a history of incurring significant net operating losses and expects to continue to incur substantial expenses and operating losses for the foreseeable future.
• There is no assurance that the company will be able to obtain additional debt or equity financing on acceptable terms or generate product revenue or revenue from collaboration partners on a timely basis or at all.
• Failure to obtain sufficient funds when needed could have a material adverse effect on the company's business, results of operations, and financial condition.
• The scope, progress, results, and costs of product discovery, preclinical studies, and clinical trials are uncertain and may require more time and resources than currently expected.
• Regulatory agencies may require redesign or modification of trials or studies, or additional trials, leading to increased expenses and delays.
• Delays in patient enrollment or completion of clinical trials could increase costs and push back timelines for product candidate development.
• Raising additional capital through equity offerings will dilute stockholders' ownership interests, and debt financing may involve restrictive covenants.
• If additional funds are raised through collaborations, the company may have to relinquish valuable rights to its technologies, future revenue streams, or product candidates.
• Product candidates, if approved, may not achieve commercial success, and product revenues are not expected for many years, if at all.
• Inflation may increase costs of labor, goods, and services, impacting financial performance.

Future Outlook

The company expects to continue incurring significant expenses and operating losses as it advances its clinical trials for VY7523, invests in proprietary platforms and programs, and initiates additional preclinical studies and clinical trials. It anticipates submitting an IND for VY1706 and initiating a clinical trial in 2026. Neurocrine is expected to provide an update on IND filing timelines for their FA and GBA1 Programs by the end of 2025, with potential clinical trial initiations in 2026. The company projects its existing cash, cash equivalents, and marketable securities, along with expected reimbursements and interest income, to be sufficient to meet operating and capital expenditure requirements into 2028. However, it will need substantial additional funding for continuing operations and future commercialization efforts.

Management Comments

• We expect our expenses to continue to increase as we continue the research and development of, conduct clinical trials of, and seek marketing approval for our product candidates, including in our ongoing Phase 1 MAD clinical trial to evaluate VY7523.
• We expect to incur increasing costs associated with operating as a public company, executing financial statement controls, satisfying regulatory and quality standards, fulfilling healthcare compliance requirements, and maintaining product, clinical trial and directors and officers liability insurance coverage.
• We also anticipate the cost of goods and services and the levels of compensation paid to employees will increase due to the current inflationary conditions existing in the general economy.

Industry Context

Voyager Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on neurogenetic medicines. The industry is characterized by long development timelines, high R&D costs, and significant regulatory hurdles. The company's reliance on its TRACER AAV capsid discovery platform and the newer Voyager NeuroShuttle non-viral platform positions it in the advanced gene therapy and targeted delivery space. Recent program terminations by major partners like Novartis and Neurocrine highlight the inherent risks and high attrition rates in drug development, even for promising early-stage assets. The deprioritization of internal programs suggests a strategic refocusing to conserve capital and concentrate on core assets, a common trend in biotech when facing financial pressures or shifting pipeline priorities.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company was not a party to any material legal matters or claims as of September 30, 2025, or December 31, 2024.

Related Party Transactions

• Payments of $93,900 (three months ended Sep 30, 2025) and $373,200 (nine months ended Sep 30, 2025) were made to Dinah Sah, Ph.D., the company's former Chief Scientific Officer, for scientific advisory services.
• Related party collaboration receivable from Neurocrine Biosciences was $851,000 as of September 30, 2025, up from $676,000 at December 31, 2024.
• Deferred revenue from Neurocrine Biosciences was $12,049,000 as of September 30, 2025, down from $30,397,000 at December 31, 2024.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity offerings needed to fund operations.
• Employees may be impacted by continued cost management and strategic reprioritization, following a reduction in force in Q2 2025.
• Collaboration partners (Novartis, Neurocrine, Alexion) are critical for funding and program advancement, but recent terminations/discontinuations indicate evolving relationships and risks.
• Patients awaiting treatments for neurological diseases may see shifts in program focus and timelines due to deprioritizations and collaboration changes.

Next Steps

• Generate initial data from the Phase 1 MAD clinical trial of VY7523 in the second half of 2026.
• Submit an Investigational New Drug (IND) application and initiate a clinical trial for the VY1706 program in 2026.
• Neurocrine to provide an update on IND filing timelines for their FA Program and GBA1 Program by the end of 2025.
• Potential initiation of clinical trials for Neurocrine's FA and GBA1 Programs in 2026, pending toxicology study outcomes, FDA IND acceptance, and internal strategic assessment.
• Receive a $3.0 million milestone payment from Neurocrine in Q4 2025 for a preclinical toxicology study initiation.
• Continue investing in proprietary antibody, gene therapy, vectorized antibody, and non-viral therapeutic platforms and programs.
• Continue investing in and supporting the TRACER discovery platform.
• Increase investment in the discovery and development of modalities for receptor-mediated non-viral delivery of therapeutic payloads to the CNS.
• Conduct joint research and development under strategic collaborations with Neurocrine and Novartis.
• Identify additional diseases for treatment with AAV gene therapies and develop additional programs or product candidates.
• Seek marketing and regulatory approvals for product candidates that successfully complete clinical development.
• Maintain, expand, protect, and enforce the intellectual property portfolio.

Key Dates

Recommendation

The company's financial performance has significantly deteriorated, marked by a substantial increase in net loss and cash burn, and a sharp decline in collaboration revenue. The partial termination of two Novartis programs and the discontinuation of two Neurocrine programs represent material setbacks, reducing future milestone and royalty potential. While the cash runway into 2028 provides some near-term stability, the ongoing need for substantial additional funding, coupled with the high-risk nature of drug development and recent program setbacks, points to a challenging outlook. These factors suggest a weakening financial and operational position, warranting a 'sell' recommendation for a seasoned investor.

Keywords

Voyager Therapeutics, VYGR, Gene Therapy, Neurological Diseases, Alzheimer's Disease, Parkinson's Disease, Friedreich's Ataxia, TRACER Capsids, NeuroShuttle, Novartis, Neurocrine Biosciences, Alexion, SEC Filing, 10-Q, Biotechnology, Clinical Trials, Drug Development, Financial Results